Analysts Issue Forecasts for GPCR FY2030 Earnings

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) – Equities researchers at HC Wainwright issued their FY2030 earnings per share estimates for shares of Structure Therapeutics in a research report issued on Wednesday, February 11th. HC Wainwright analyst A. Ghosh anticipates that the company will post earnings per share of ($1.74) for the year. HC Wainwright currently has a “Buy” rating and a $90.00 price objective on the stock. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.82) per share.

A number of other equities research analysts also recently weighed in on GPCR. Wall Street Zen downgraded shares of Structure Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. Jefferies Financial Group set a $125.00 price objective on shares of Structure Therapeutics and gave the stock a “buy” rating in a report on Thursday, December 11th. Stifel Nicolaus lifted their target price on shares of Structure Therapeutics from $50.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Morgan Stanley increased their price target on shares of Structure Therapeutics from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. Finally, BMO Capital Markets restated an “outperform” rating on shares of Structure Therapeutics in a research note on Tuesday, January 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Structure Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $104.45.

Structure Therapeutics Trading Down 2.9%

GPCR opened at $69.97 on Friday. The stock’s 50 day simple moving average is $75.01 and its 200-day simple moving average is $43.04. The stock has a market cap of $4.25 billion, a PE ratio of -57.35 and a beta of -2.06. Structure Therapeutics has a 1 year low of $13.22 and a 1 year high of $94.90.

Hedge Funds Weigh In On Structure Therapeutics

Several institutional investors have recently bought and sold shares of GPCR. Marshall Wace LLP bought a new stake in Structure Therapeutics during the fourth quarter worth $11,725,000. The Manufacturers Life Insurance Company grew its holdings in Structure Therapeutics by 237.8% in the 4th quarter. The Manufacturers Life Insurance Company now owns 96,387 shares of the company’s stock valued at $6,533,000 after buying an additional 67,855 shares in the last quarter. Stifel Financial Corp acquired a new stake in Structure Therapeutics in the 4th quarter worth about $336,000. Morgan Stanley boosted its stake in shares of Structure Therapeutics by 261.4% in the fourth quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock valued at $145,209,000 after buying an additional 1,510,093 shares during the period. Finally, Brandywine Managers LLC increased its position in shares of Structure Therapeutics by 20.8% in the fourth quarter. Brandywine Managers LLC now owns 13,357 shares of the company’s stock worth $929,000 after purchasing an additional 2,300 shares during the period. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.